Prostatic peptides for the correction of pathospermia in patients with chronic bacterial prostatitis

Abstract

The study aims to assess the effectiveness of prostatic biopeptides in the comprehensive treatment of prospermia in men with chronic bacterial prostatitis. Microscopic and bacteriological examination of the prostate gland secretion was performed in order to confirm the presence of the disease. The findings of spermograms were interpreted according to the reference values of the ejaculate parameters recommended by WHO in 2010. All patients were divided into 2 groups depending on the therapy. The patients in both groups received the standard 4-week nonsurgical therapy (antibiotics, α-blockers, nonsteroidal anti-inflammatory drugs). After completing the course of standard therapy, patients of Group 1 (31 people) received a standard amount of antioxidants for the following 4 weeks to correct prospermia. In addition to antioxidants, the patients of Group 2 (37 people) were assigned to rectal administration of prostate extract suppositories, one suppository once a day. It has been established that the long-term drug therapy is required for the correction of prospermia in patients with chronic bacterial prostatitis. The standard nonsurgical therapy consisting of antibiotics, β-blockers and nonsteroidal anti-inflammatory drugs does not lead to a significant improvement in the key ejaculate parameters. The use of prostatic biopeptides improves the qualitative and quantitative characteristics of sperm motility, which is a valuable result of therapy for patients with chronic bacterial prostatitis, who make reproductive life plans.

Keywords

• chronic prostatitis
• asthenozoospermia
• patospermia
• prostatic biopeptides
• prostate extract
• spermogram